Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Reexamination Certificate
1998-08-27
2004-04-27
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
C424S451000, C424S456000, C424S464000, C424S474000, C424S478000, C424S480000, C424S482000, C424S489000, C514S925000, C514S962000
Reexamination Certificate
active
06726927
ABSTRACT:
BACKGROUND OF THE INVENTION
U.S. Pat. No. 4,255,431 describes a compound 2-[2-(3,5-dimethyl-4-methoxy)-pyridyl methyl sulfinyl]-(5-methoxy)-benzimidazole (Omeprazole) or pharmaceutically acceptable salt or non-toxic acid addition salt as a therapeutic compound for mammals including man, suffering from gastric acid secretion disturbances.
Omeprazole, however is only stable in basic pH conditions and degrades rapidly in neutral or acid pH environment. For this reason the omeprazole oral dosage form must be protected, not only from the acidic inert ingredients used to make a dosage form but also from the acidic gastric fluid in order to intactly reach the absorption site in the small intestine.
A study [Drug Dev. Ind. Pharm. 21(8), 965 (1995)] showed the effect of pH on the stability of omeprazole solution. The pH-decomposition rate profile curve indicated that the maximum stability was at pH 11. Below pH 7.8 the decomposition was very fast.
A survey of the stability of Omeprazole products from 13 countries was reported [Drug Dev. Ind. Pharm. 22(12), 1173(1996)]. The results of this independent survey of the stability of omeprazole solid dosage forms (20 mg) show that product available in many countries worldwide exhibits a very wide range of stability characteristics. Only 18% of total products tested (34) were considered to demonstrate good physical and chemical stability over the course of the study.
U.S. Pat. No. 4,628,098 discloses that: Lansoprazole is a substituted benzimidazole 2-[[[3-methyl-4-(2,2,2-trifluroethoxy)-2-pyridyl]methyl]sulfinyl] benzimidazole, a compound and a pharmacologically acceptable salt thereof that inhibits gastric acid secretion.
Lansoprazole is relatively stable when exposed to light. The compound degrades in aqueous solution, the rate of degradation increasing with decreasing pH.
It is well known in the pharmaceutical industry that an enteric coating technology is the most efficient means to protect acid unstable medication from the attack of the gastric fluid and can rapidly release the active drug in the proximal part of the gastrointestinal canal.
An enteric coated dosage form of omeprazole was reported in 1985 by Pilbrant and Cederberg (Scand. J. Gastroenterology 1985; 20 (supp.108) p. 113-120). It was found later that the stability of this dosage form was not sufficient for a long term commercial purpose.
Because of the acidic property of the enteric coating polymer, the omeprazole or lansoprazole will degrade and diminish its therapeutic value by direct or indirect contact with it during or after the coating process, even in the presence of alkaline inert ingredients with the active drug in the core particles.
DE—AI number 3046 559 teaches a two layer coating system for a dosage form in which the first coating is a water insoluble layer of microcrystalline cellulose and then enteric coating as the second layer to release the active drug in the colon.
WO number 85/03436 describes a technique to mix active drug with buffering components (i.e. sodium dihydrogen phosphate) to maintain a constant pH in a core for particular purposes. The core is coated with a layer which controls the diffusions.
All of these inventions when applied to omeprazole's or lansoprazole's case will not give either an adequate release of active drug or storage stability of such dosage form.
U.S. Pat. No. 4,786,505 teaches an art to make an oral pharmaceutical preparation comprising (1) a core consisting of omeprazole plus an alkaline reacting compound (2) an inert subcoating of core (3) an enteric coating of subcoated core and to use it in the treatment of gastrointestinal disease.
This technique requires a series of cumbersome and laborious pharmaceutical processes: 1) preparation of the core, which should be suitable for multilayer coating 2) Coating the core with one or more layers of an inert subcoating containing one or more alkaline substances 3) applying an outer enteric coating to the subcoated core 4) make the pharmaceutical preparation for therapeutical use.
U.S. Pat. No. 5,232,706 claims an oral pharmaceutical preparation of omeprazole or an alkali salt of omeprazole and a process for producing such preparation. The design principle of the preparation is basically similar to the U.S. Pat. No. 4,786,505. This preparation is comprised of: 1) a nucleus of active drug and first basic organic compound; 2) a first coating of nucleus containing at least a layer of a basic water soluble excipient and a second basic organic compound; and 3) a second coating formed by an enteric coating.
The major difference between U.S. Pat. Nos. 5,232,706 and 4,786,505 is the type of basic compound used; the former uses basic organic compound the later uses inorganic alkaline reaction compounds in core and in subcoating.
U.S. Pat. No. 5,385,739 relates to a stable formulation of Omeprazole microgranules containing a neutral core of sugar and starch coated with an active layer of drug and mannitol powder mixture with the aid of a solution of a binding agent in water plus ethanol. An additional protective layer of mannitol and sugar syrup is then applied prior to the final gastroprotection coating.
The art of coating a powder mixture containing an active ingredient onto the core of sugar and starch by using a binding solution is a rather difficult process to obtain uniform drug core granules.
In addition, two applications of aqueous solution involving the direct contact with Omeprazole, in the coating process, may effect the stability of this moisture-sensitive drug.
U.S. Pat. No. 5,399,700 teaches a method for stabilizing an acid unstable benzimidazole derivative, by forming an inclusion complex of omeprazole with cyclodextrin.
This inclusion complex was synthesized in an aqueous alkaline solution at 40°-70° C. and then used to manufacture a tablet which is first coated by a water soluble substance and then with an enteric substance to form an enteric coated oral drug.
The safety of cyclodexrin for human oral dosage form needs to be clarified. Even if the acid stability and dissolution characterization of this inclusion complex has been well demonstrated in vitro, its behavior in vivo is not referenced in this patent.
U.S. Pat. No. 4,689,333 claims a pharmaceutical composition for preventing or treating digestive ulcers or gastritis which contains an effective amount of Lansoprazole or a pharmacologically acceptable salt thereof and pharmacologically acceptable carriers.
A study [Drug Dev. Ind. pharm. 18 (13), 1437 (1992)] reported that enteric granule formulations for Lansoprazole was established, however, it was difficult because some of the excipients needed for these formulations are incompatible with the drug. The alkaline stabilizers were then screened and the optimal pH stability of 9 was suggested in this paper.
A continued study from the above mentioned effort [Drug Dev. Ind. pharm. 20(9), 1661 (1994)] attempted to prepare more stable enteric granules without using these troublesome excipients by using a centrifugal fluid-bed granulator instead of an extruder-spheronizer. It was said that with this method more stable enteric granules could be obtained. The utilization of special sophisticated equipment to achieve the stable granules may suffer economical disadvantages.
U.S. Pat. No. 5,026,560 discloses spherical granules having a seed core coated with a binder and spraying powder containing lansoprazole as active drug, low substituted hydroxypropylcellulose and magnesium or calcium carbonate as alkaline agents. The powder coated core is further coated with spraying powder of low substituted hydroxypropylcellulose and then with enteric coating agent.
Technically, powder coating in pharmaceutical manufacturing brings forth issues such as content uniformity of the active on the seed core, laborious process attention and time consumption. It therefore tremendously increases the cost of the product.
U.S. Pat. No. 5,045,321 describes a pharmaceutical composition for coated tablets or granules,
Page Thurman K.
Sage Pharmaceuticals, Inc.
Sheikh Humera N.
Walker L.L.P. Jackson
LandOfFree
Preparation of enteric pharmaceutical dosage forms for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preparation of enteric pharmaceutical dosage forms for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation of enteric pharmaceutical dosage forms for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3272601